| First Author | He M | Year | 2023 |
| Journal | Science | Volume | 379 |
| Issue | 6633 | Pages | eabg2752 |
| PubMed ID | 36795805 | Mgi Jnum | J:341597 |
| Mgi Id | MGI:7442108 | Doi | 10.1126/science.abg2752 |
| Citation | He M, et al. (2023) CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science 379(6633):eabg2752 |
| abstractText | The induction of proinflammatory T cells by dendritic cell (DC) subtypes is critical for antitumor responses and effective immune checkpoint blockade (ICB) therapy. Here, we show that human CD1c(+)CD5(+) DCs are reduced in melanoma-affected lymph nodes, with CD5 expression on DCs correlating with patient survival. Activating CD5 on DCs enhanced T cell priming and improved survival after ICB therapy. CD5(+) DC numbers increased during ICB therapy, and low interleukin-6 (IL-6) concentrations promoted their de novo differentiation. Mechanistically, CD5 expression by DCs was required to generate optimally protective CD5(hi) T helper and CD8(+) T cells; further, deletion of CD5 from T cells dampened tumor elimination in response to ICB therapy in vivo. Thus, CD5(+) DCs are an essential component of optimal ICB therapy. |
